CV9103 encodes four TAAs in prostate cancer: PSA, PSMA, PSCA, and STEAP, and it is the first-in-human tested mRNA vaccine.175 Two clinical trials on the use of CV1903 in prostate cancer have been conducted. This evidence concerns the gene FOLH1 and prostate cancer.